VivoSeq
Immunology

Angioedema

26

Pipeline Programs↗

5

Active Trials↗

13

Companies Involved↗

Angioedema is an emerging landscape with 26 programs across 13 companies. The most active players are Glaxo Dba Glaxosmithkline, Bayer, Eli Lilly. 2 therapies are approved with 10 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

51/100

Pipeline Velocity

6/100

Mech. Concentration

17/100

Completion Rate

76/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Glaxo Dba Glaxosmithkline

1 program

Phase 2Bayer logo

Bayer

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3CSL Behring logo

CSL Behring

1 program

Phase 3Roche logo

Roche

2 programs

Phase 3M

Milestone Pharmaceuticals Inc.

1 program

Approved

Pipeline

Programs by Phase

Analysis

Modality Breakdown

75%

Small molecule

21 of 28 classified programs — the dominant modality here.

25%ALL OTHERSPeptide414%Monoclonal antibody311%

Small molecule leads; the ring shows all 28 classified programs, each share of the total. Modality classified for 94% of 32 pipeline programs.

Analysis

Trial Status

29

clinical trials

Completed16 · 55%
Terminated5 · 17%
Recruiting3 · 10%
Not yet recruiting1 · 3%
Available1 · 3%
Active, not recruiting1 · 3%
Other2 · 7%

Clinical Trials

Trial Activity

29 trials

Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
Recruiting·—·Phase 3·NCT06679881·170 enrolled
Lanadelumab in Long-term Prophylaxis of Acquired Angioedema
Recruiting·—·Phase 4·NCT06818474·5 enrolled
A Phase 3, Randomized, Double-blind, Placebo-controlled, 3-Part Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant Extended-release (XR) Tablet for Prophylaxis and Deucrictibant Immediate-release (IR) Capsule for On-demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency
Recruiting·—·Phase 3·NCT07266805·32 enrolled
Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE
Active, not recruiting·—·Phase 3·NCT06669754·81 enrolled
Safety and Efficacy of Conestat Alfa for ACE-Induced Angioedema
Not yet recruiting·UUniversity of Cincinnati·Phase 3·NCT06679426·24 enrolled
A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor
Completed·Takeda logoTakeda·Phase 3·NCT04444895·73 enrolled
Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
Completed·Takeda logoTakeda·Phase 3·NCT02741596·212 enrolled
EDEMA2: Evaluation of DX-88's Effect in Mitigating Angioedema
Completed·Takeda logoTakeda·Phase 2·NCT01826916·77 enrolled
Pharmacogenetics of Ace Inhibitor-Associated Angioedema
Completed·VVanderbilt University·N/A·NCT01413542·44 enrolled
AMelioration of Angiotensin Converting Enzyme Inhibitor Induced Angioedema Study
Completed·TTechnical University of Munich·Phase 2·NCT01154361
Efficacy and Safety Study of DX-2930 to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
Completed·Takeda logoTakeda·Phase 3·NCT02586805·125 enrolled
The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment
Completed·UUniversity of Nebraska·N/A·NCT01371877·42 enrolled
C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema
Completed·PProthya Biosolutions·Phase 3·NCT00125151·15 enrolled
Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy
Completed·UUniversity of Wisconsin, Madison·Phase 4·NCT02966314·12 enrolled
Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy
Completed·Novartis logoNovartis·Phase 3·NCT01723072·91 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)